Improved metabolic control preserved beta-cell function two years after diagnosis of insulin-dependent diabetes mellitus;L'amelioration du controle metabolique preserve la fonction β-insulaire deux ans apres le diagnostique du diabete insulino-dependant

Diabetes and Metabolism

Volumn 23, Issue 4, 1997, Pages 314-319

  Montanya, E ^a   Fernandez Castaner M ^b   Soler, J ^b  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b NONE

Author keywords

C peptide; HbA1; Intensive insulin therapy

Indexed keywords

HEMOGLOBIN A1C; INSULIN;

ADULT; ARTICLE; DIABETES CONTROL; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; PANCREAS ISLET BETA CELL; TREATMENT OUTCOME;

ADULT; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; MALE; PROSPECTIVE STUDIES;

EID: 0030800537     PISSN: 03381684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Agner T, Dam P, Binder C. Remission in IDDM. Prospective study of basal C-peptide and insulin dose in 268 consecutive patients. Diabetes Care, 1987, 10, 164-169.
2. Yilmaz MT. The remission concept in type 1 diabetes and its significance in immune intervention. Diabetes Metab Rev, 1993, 4, 337-348.
3. Allen C, Zaccaro DJ, Palta M, Klein R, Duck SC, D'Alessio DJ. Glycemic control in early IDDM. Diabetes Care, 1992, 4, 980-987.
4. The DCCT Research Group. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual b-cell function : observations during eligibility testing for the diabetes control and complications trial (DCCT). J Clin Endoc Metab, 1987, 65, 30-35.
5. Snorgaard O, Lassen LH, Binder C. Homogeneity in pattern of decline of beta-cell function in IDDM. Prospective study of 204 consecutive cases followed for 7.4 yr. Diabetes Care, 1992, 15, 1009-1013.
6. Sochett EB, Daneman D, Clarson C, Ehrlich RM. Factors affecting and patterns of residual insulin secretion during the first year of type 1 (insulin-dependent) diabetes mellitus in children. Diabetologia, 1987, 30, 443-449.
7. Schiffrin A, Suissa S, Poussier P, Guttmann R. Prospective study of predictors of beta cell survival in type 1 diabetes. Diabetes, 1988,37, 920-925.
8. Montana E, Fernandez-Castaner M, Rosel P, Gomez, J, Soler J. Age, sex and ICA influence on beta cell secretion during the first year after the diagnosis of type 1 diabetes mellitus. Diabet Metab, 1991, 17, 460-468.
9. Schiffrin A, Suissa S, Weitzner G, Poussier P, Lalla D. Factors predicting course of beta cell function in IDDM. Diabetes Care, 1992, 15, 997-1001.
10. Martin S, Pawlowski B, Greulich B, Ziegler A, Mandrup-Poulsen T, Mahon J. Natural course of remission in IDDM during 1st yr after diagnosis. Diabetes Care, 1992, 15, 66-74.
11. Hramrak IM, Dupre J, Finegood DT. Determinants of clinical remission in recent-onset IDDM. Diabetes Care, 1993, 16, 125-132.
12. Björk E, Berne C. Kämpe O, Wibell L, Oskarsson P, Karlsson FA. Diazoxide treatment at onset preserves residual insulin secretion in adults with autoimmune diabetes. Diabetes, 1996, 45, 1427-1430.
13. Linn T, Geyer R, Prassek S, Laube H. Effect of dietary protein intake on insulin secretion and glucose metabolism in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1996, 81, 3938-3943.
14. Feutren G, Assan R, Karsenty G et al. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Lancet, 1986, 2, 119-123.
15. Bougneres PF, Carel JC, Castano L et al. Factors associated with early remission of Type I diabetes in children treated with cyclosporine. N Engl J Med, 1988, 318, 663-670.
16. Mirouze J, Selam JL, Pham TC, Mendoza E, Orsetti A. Sustained insulin-induced remissions of juvenile diabetes by means of an external artificial pancreas. Diabetologia. 1978, 14, 223-227.
17. Madsbad S, Krarup T, Faber OK, Binder C, Regeur L. The transient effect of strict metabolic control on beta cell function in newly diagnosed type 1 (insulin-dependent) diabetic patients. Diabetologia, 1982, 22, 16-22.
18. Perlman K, Ehrlich RM, Filler RM, Albisser AM. Sustained normoglycemia in newly diagnosed type 1 diabetic subjects. Diabetes, 1984, 33, 995-1001.
19. Shah SC, Malone JI, Simpson NE. A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes mellitus. N Engl J Med, 1989, 320, 550-554.
20. National Diabetes Data Group. Classification and diagnosis of Diabetes Mellitus and other categories of glucose intolerance. Diabetes, 1979, 28, 1039-1057.
21. Botazzo GF, Florin-Christensen A, Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet, 1974, 2, 1279-1282.
22. Bailar III, JC, Morteller F. Medical Uses of Statistics. NEJM Books. Whaltan, Massachusetts, 1986.
23. Bergnestal RM, Dupre J, Lawson PM, Rubenstei AH, for the Kroc Collaborative Study Group. Observations on C-peptide and free insulin in the blood during continuous subcutaneous insulin infusion and conventional insulin therapy. Diabetes; 1985, 34 (suppl. 3), 31-36.
24. Faber OK. Beta cell function and diabetic control in insulin-dependent diabetes mellitus. Acta Endocrinol, 1985, 110 (suppl. 272), 73-78.
25. c : relation to age, duration, C-peptide, insulin dose and one or two insulin injections. Diabetes Care, 1982, 5, 399-403.
26. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med, 1993, 329, 977-986.
27. Dahl-Jorgensen K, Brinchmann-Hansen O, Bangstad H-J, Hanssen KF. Blood glucose control and microvascular complications. What do we know ? Diabetologia, 1994, 37, 1172-1177.